SF 0166

Drug Profile

SF 0166

Alternative Names: SF0166

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SciFluor Life Sciences
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 26 Jun 2017 SciFluor Life Sciences completes a phase I/II trial in Age-related macular degeneration in USA (Ophthalmic) (NCT02914639)
  • 16 May 2017 SciFluor Life Sciences completes a phase I/II trial in Diabetic macular oedema in USA (Ophthalmic) (NCT02914613)
  • 30 Sep 2016 Phase-I/II clinical trials in Age-related macular degeneration in USA (Ophthalmic) (NCT02914639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top